Showing posts with label fetal growth restriction. Show all posts
Showing posts with label fetal growth restriction. Show all posts

Sunday, August 27, 2017

Trying to Understand Stillbirths


Stillbirths affects 1% of all pregnancies in US, amounting to nearly 24,000 deaths every year. Recent advances in medicine has brought down the neonatal and infant mortality considerably in last decade, but the decline is still birth rate is very slow.

A lack of understanding of the mechanisms behind it coupled with inability to predict stillbirth has prevented significant improvement in stillbirths’ rate.

Although altered fetal growth and placental abnormalities are strongest predictors of stillbirths but all patients with placental abnormalities do not end up in stillbirths, reflecting our lack of understanding of this interrelationship.

This population based case control study included 613 women who had stillbirths and 1747 women who had live births and who consented to placental pathological examination from 59 hospitals in 5 geographic areas in the U.S.

Study was published online August 18, 2017 in Journal PloS one.
About 15 placental pathologies were most prevalent in women with stillbirths and fetal growth abnormalities.

Out of 15, ten were also associated with fetal growth retardations. These are: single umbilical artery; velamentous insertion; terminal villous immaturity; retroplacental hematoma; parenchymal infarction; intraparenchymal thrombus; avascular villi; placental edema; placental weight; ratio birth weight/placental weight)

The other 5 (acute chorioamnionitis of placental membranes; acute chorioamionitis of chorionic plate; chorionic plate vascular degenerative changes; perivillous, intervillous fibrin, fibrinoid deposition; fetal vascular thrombi in the chorionic plate) resulted in stillbirths without altered fetal growth.  

Terminal villous hypoplasia was equally common in live born and still born fetuses with altered fetal growth.

Maternal factors associated with still births were gestational hypertension/pre-eclampsia (20% versus 11%, p<0.001), hypertension before pregnancy (11% versus 5%, p<0.001), and pregestational diabetes (7% versus 2%, p<0.001)

Fetal factors associated with still births were congenital malformations (13% versus 3%, p<0.001), lower birth weight (median 1,949 versus 3,321 grams, p<0.001), and lower GA (median 33 versus 39 weeks, p<0.001).

The study results suggest that different mechanisms exist for disruption in placental function and the results vary according to timing of gestation. An acute insult results in still births but no fetal growth alterations while a chronic, low level insult results in fetal growth retardation which may end up in still births.

Some of these placental findings can be diagnosed with prenatal ultrasound and pregnancies managed accordingly, Similarly, birth weight to placental weight ratio could be estimated antenatally by ultrasound and those pregnancies with abnormal ratio and at risk of stillbirths could benefit from early  term delivery.

Access the abstract, Full Text.


Friday, March 10, 2017

New use of old drug: Sildenafil Citrate (Viagra) improves amniotic fluid index in oligohydramnios.

Pfizer.com 

Sildenafil Citrate (Viagra) improves amniotic fluid index in pregnancies complicated by oligohydramnios according to a new study published ahead of print on March 6,2017 in Journal of Obstetrics and Gynecology.[1]

Viagra, a specific phosphodiesterase-5 inhibitor, has recently been proposed as a potential therapeutic strategy to maintain placental function and increase the amniotic fluid index (AFI).

This was an open-label randomized trial, carried out over a period of one year and recruited a total of 184 women. The study included all women at 30 weeks or more in pregnancy with oligohydramnios detected during routine sonography. No specific cause or etiology was detected for oligohydramnios in all these women.

The women were randomized to receive either Sildenafil Citrate 25 mg three times a day along with intravenous infusion of 2 L isotonic solution (82 women) or just fluids only (84 women). All women were hospitalized for initial 24 hours and received the IV fluids.  

The women were followed up for 6 weeks on the basis of outpatient monitoring with NST, USG and biophysical profile. Patient is readmitted if the AFI drops below 5 for Intravenous fluid therapy. Final assessment of the amniotic fluid volume is done at 6 weeks or before delivery if she went into labor before completing 6 weeks.

It was seen that women who received Sildenafil have considerable good amniotic fluid at follow up with AFI of 11.5 vs 5.4 in the control group. (P=.02).

The women in sildenafil group also went further into pregnancy with mean gestational age of 38.3 weeks as compared to 36 weeks. (P=.001). These women had one third the rate of Cesarean section and one fourth neonatal intensive care admission as compared to placebo group.

The authors concluded that “Sildenafil citrate increases amniotic fluid volume in pregnancies complicated by oligohydramnios.”

The proposed mechanism is vasodilatation of small myometrial vessels, thereby increasing the placental perfusion which leads to improvement in amniotic fluid index, fetal weight, and even uterine and umbilical artery Doppler patterns.

Currently there is no effective therapy for early onset IUGR or oligohydramnios.
Sildenafil citrate in the same dose has also shown promising results in improving the birth outcomes in early and late onset IUGR.[2]

Preliminary studies have also shown that it is effective in early onset preeclampsia to improve fetal growth retardation, but more randomized trials are needed.[3]


The trial is registered with Clinicaltrials.gov number NCT02372487



[1] http://journals.lww.com/greenjournal/toc/publishahead
[2] http://www.ijrcog.org/index.php/ijrcog/article/viewFile/1603/1429
[3] https://obgynupdated.blogspot.com/2016/07/new-use-of-old-drug-sildenafil-citrate.html